P1, N=94, Active, not recruiting, Arcus Biosciences, Inc. | Trial completion date: Jan 2024 --> Mar 2025 | Trial primary completion date: Jan 2024 --> Mar 2025
9 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
Safety and efficacy data will be analyzed using summary statistics and Kaplan Meier estimates as appropriate; PK parameters will be estimated using noncompartmental methods. ARC-12 is actively recruiting at sites in the United States (NCT04772989).
3 years ago
Clinical • P1 data
|
TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)